公司将持续深耕合成生物学、工业发酵、益生菌、细胞治疗等核心应用场景。其技术不仅能助 力高效菌种筛选与工艺优化，更能为CAR-T等细胞药物和益生菌的研发与质控提供活体、无 损的单细胞代谢动态数据，直击产业对细胞功能量化监控的核心需求。通过提供从仪器到场景 化解决方案的全链条支持，星赛生物正为生物制造体系的升级与细胞药物产业的发展构建坚实 的工具基础。 此前星赛生物共获得 三轮融资 ，分别是： 2023 年 12 月 近 亿 元 人 民 币 A 轮 融 资 ， 由 恒 旭 资 本 领 投 ， 北 洋 海 棠 基 金 跟 投 。 2023 年 7 月 Pre-A轮融资数千万元人民币，投资方包括高科新浚、浙江衡吉。2022年12月由茅台基金公 司管理的茅台科创基金投资进行的 战略融资 。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 青 岛星赛生物科技有限公司（以下简称"星赛生物"）宣布完成近亿元人民币新一轮融 资。 本轮融资将围绕"技术深度融合、智能生态构建、全球市场拓展"三大战略方向，全面推 动星赛生物从"关键技术突破与产品化"阶段 ...

Group 1 - The event "Synthetic Biology Manufacturing Innovation and Entrepreneurship Competition" held in Changde showcased the integration of industry, capital, and urban strategy, attracting nearly 1,000 experts and representatives from academia, industry, and investment [1][2] - The competition featured 60 teams selected from 338 projects, focusing on nine cutting-edge areas including biomedicine and AI synthetic biology manufacturing, highlighting the event's broad participation and influence [2][4] - The competition served as a key hub for linking innovative resources and industrial ecosystems, with a diverse activity matrix that included parallel events aimed at promoting collaboration and resource integration [7][9] Group 2 - The competition presented various projects demonstrating the transition of synthetic biology from laboratory to industrial application, addressing challenges in traditional agriculture and healthcare [4][19] - The establishment of the Hunan Synthetic Biology Manufacturing Standardization Technical Committee during the event marked a new phase in industry development, focusing on building common rules [7] - The awards ceremony recognized outstanding projects, providing winners with access to government funding and direct connections to industry leaders, facilitating the transition from technology to market [14][16] Group 3 - The successful hosting of the competition signifies a new starting point for Changde's industrial development, transitioning from reliance on traditional resources to becoming a hub for innovation and ecological attractiveness [19][20] - The event demonstrated a comprehensive approach to empowering the industry, including standardization, application scenario openness, and capital integration, enhancing long-term competitiveness [19] - Changde aims to merge its historical and cultural strengths with cutting-edge synthetic biology, showcasing its unique capability to drive future industrial development [19][20]

Core Viewpoint - The restructuring plan of Hunan pharmaceutical company *ST Jingfeng has made significant progress, with a total investment of approximately 2.061 billion yuan from Shijiazhuang Pharmaceutical Group and 18 other participants, marking a substantial increase from the original plan of 648 million yuan [2]. Group 1: Restructuring and Investment - The restructuring plan involves the transfer of 879,774,351 shares to new investors, which is seen as a positive signal for the company [2]. - The new investor list includes representatives from Changde City State-owned Capital and existing shareholders like China Great Wall Asset Management, along with several new financial investors [2]. - The total consideration for the shares has increased significantly, indicating strong market confidence in the company's future [2]. Group 2: Management Changes - Cai Lei, son of the actual controller Cai Dongchen, has been appointed to key management positions, including Vice Chairman, Executive Director, and CEO, marking a significant generational shift in leadership [3]. - Cai Lei has a strong academic background and has held various roles within the company, focusing on overseas R&D and sales [3]. - The management transition is viewed as a step towards Cai Lei gradually taking over the management functions of the group [3]. Group 3: Business Focus and Strategy - Jingfeng Pharmaceutical focuses on popular treatment areas such as cardiovascular diseases, orthopedic pain, and oncology, with key products including heart and brain calming capsules and sodium hyaluronate injections [4]. - The restructuring plan aims to consolidate existing product advantages while enhancing marketing and new product development, including expanding production capacity and advancing oncology product research [4]. - The company plans to leverage Changde City's resources and policies in the biopharmaceutical sector to foster a second growth curve, focusing on synthetic biology and innovative drug-device integration [4]. Group 4: Market Position and Future Outlook - The Cai Dongchen family and Shijiazhuang Pharmaceutical Group face the challenge of gaining market recognition during the restructuring process [5]. - Shijiazhuang Pharmaceutical Group's market capitalization has risen to approximately 110 billion yuan since 2025, reflecting positive market sentiment [5]. - The future role of Jingfeng Pharmaceutical within the Shijiazhuang system remains to be seen, especially in light of the challenges faced by the innovative drug sector [6].

Core Viewpoint - The leadership transition at CSPC Pharmaceutical Group (石药集团) to Cai Lei coincides with the significant restructuring of Jingfeng Pharmaceutical (景峰医药), which is seen as a critical test for the new management [1][2]. Group 1: Restructuring of Jingfeng Pharmaceutical - CSPC, as the lead investor, along with 18 other investors, will acquire a total of 879,774,351 shares of Jingfeng Pharmaceutical for approximately 2.061 billion yuan, a substantial increase from the previously planned 648 million yuan [1]. - The restructuring plan includes a focus on existing advantageous products, enhancing marketing capabilities, and innovating new products, particularly in cardiovascular, orthopedic pain, and oncology sectors [3]. - The restructuring will leverage the support from Changde City for the biopharmaceutical industry, aiming to cultivate biopharmaceuticals as a second growth curve for the company [3]. Group 2: Leadership Changes - Cai Lei, the son of the company's actual controller, has recently been appointed as CEO, marking a significant step in the management transition within the company [2]. - Cai Lei has a strong academic background and extensive experience within the company, having held various leadership roles prior to his current position [2]. - The previous CEO, Zhang Cuilong, who served for a short period, has stepped down but will remain as an executive director [2]. Group 3: Market Performance and Future Outlook - Since the beginning of 2025, CSPC's overall market value has surged to approximately 110 billion yuan, driven by a series of asset injections and business development transactions [3]. - Newnow (新诺威), as an innovative drug capital platform under CSPC, has also seen its market value rise to 55 billion yuan [3]. - Newnow has projected a significant loss for the 2025 fiscal year, indicating challenges in traditional business areas while the role of Jingfeng Pharmaceutical in CSPC's future remains to be seen [4].

Core Insights - The collaboration between Chengzhi Life and Beijing Sport University has successfully completed clinical exploration of D-Ribose for marathon athletes, demonstrating significant benefits for heart protection and athletic performance [1][2][4] - Chengzhi Co., as a leader in synthetic biology, has achieved a milestone in the industrial application of synthetic biology technology, contributing to global health industry transformation [1][2][10] Group 1: Clinical Research Findings - The study indicates that the Lipoz D-Ribose supplement significantly enhances heart protection, athletic performance, and fatigue recovery in marathon runners [2][5] - D-Ribose acts as a "cellular energy engine," directly participating in ATP synthesis and accelerating energy regeneration, which is crucial for endurance sports like marathons [5][6] - The clinical trials involved both middle-aged and young marathon runners, showing that D-Ribose supplementation reduces muscle damage and improves recovery speed [5][6] Group 2: Technological Advancements - Chengzhi Co. has developed a fermentation method for D-Ribose production, which is environmentally friendly and avoids toxic chemicals, achieving high purity and stability [7][10] - The company has established a comprehensive intellectual property network covering various aspects of D-Ribose production and application, positioning itself as a leader in the field [10][11] Group 3: Market Strategy and Achievements - Chengzhi Co. employs a "technology + market" dual-driven strategy, enhancing its global market presence through acquisitions and partnerships [10][11] - The company has seen a 50% increase in sales of Lipoz D-Ribose in 2024, with single product sales exceeding 100 million yuan, indicating strong market demand [11][12] - Chengzhi Co. has received multiple awards and recognitions, solidifying its position as a leading brand in the D-Ribose product category [11][12]

Core Insights - The 2026 Sanya International Seed Industry Scientist Conference opened with over 30 academicians from various countries discussing new paths and opportunities for international seed industry development [4] Group 1: Conference Overview - The conference gathered more than 2,000 representatives, including over 100 agricultural university presidents and deans, focusing on cutting-edge seed technology and industry transformation [4] - The theme of the conference is "Innovation Leading Seed Industry Development, Cooperation Ensuring Global Food Security," featuring over 30 specialized forums and nearly 200 keynote reports covering key areas such as aquaculture breeding, livestock improvement, rice innovation, biotechnology, smart equipment, and functional agriculture [4] Group 2: International Collaboration and Research - The conference serves as a comprehensive international platform for strategic discussions, technological exchanges, industry cooperation, and talent cultivation, with top scientists and industry experts from countries like China, the USA, Germany, the Netherlands, and Russia engaging in deep discussions on frontier topics such as gene editing, synthetic biology, AI breeding, and nuclear technology applications in agriculture [4][5] - The event also includes the 2026 International Seed Industry Technology Expo, showcasing the latest achievements across the entire industry chain, from superior germplasm resources to new intelligent agricultural machinery and financial services [4] Group 3: Future Directions - The conference has evolved into the largest and highest-level international platform in China's seed technology field over the past five years, with a commitment to promoting collaborative innovation and international cooperation to address key challenges in the seed industry [5]

Core Breakthrough - The company Tianhe Bio's AKG and Ca-AKG products have successfully completed the Self-GRAS scientific evaluation under FDA guidelines, becoming the first domestic products to receive GRAS certification through fermentation methods, thus gaining access to the U.S. market [1] - This achievement fills a gap in domestic product process certification and marks a significant step for the company in entering the global nutrition and health market [1] Technical Strength - Tianhe Bio employs a patented whole-cell catalysis method for its CynbioX®AKG, using food-grade glutamic acid bacteria as a carrier, ensuring product safety and reducing impurities while enhancing purity [2] - The company has achieved large-scale production of CynbioX®AKG and CynbioX®Ca-AKG products, positioning itself as a global innovator in AKG applications [2] - The company has obtained multiple important certifications, including KOSHER, FSSC 22000, and HALAL, aligning its technology and quality control with international standards [2] International Standards and Market Expansion - The successful acquisition of the U.S. Self-GRAS certification demonstrates the company's international standards in product development and quality control, laying a solid foundation for expanding into the global nutrition and health market [3] - There is a growing demand for AKG components in anti-aging, sports nutrition, and weight management sectors, and the company is expected to leverage its certification advantages and technological accumulation to gain a competitive edge in the global AKG market [3]

Core Viewpoint - Dezhou City is focusing on enhancing its technological capabilities and innovation platforms to support traditional industries' transformation and the growth of emerging sectors, aiming for a significant leap from manufacturing to intelligent manufacturing by 2025 [3][4]. Group 1: Traditional Industry Transformation - The city is encouraging the application of new technologies and processes in traditional industries such as food processing and light textile to boost efficiency and innovation [3]. - A total of 144 new city-level technology innovation platforms have been established, including 72 key laboratories and 60 enterprise technology innovation workstations, to support the transformation of traditional industries [3]. Group 2: Emerging Industry Support - Dezhou is accelerating its layout in emerging industries like new-generation information technology, new energy, and new materials, focusing on areas such as carbon fiber composites and graphene [3][4]. - The city is also supporting critical components in integrated circuits and intelligent network security, aligning platform distribution with the needs of industrial transformation [4]. Group 3: Future Industry Layout - The city is proactively establishing platforms for future industries such as biomanufacturing and hydrogen energy, which are expected to drive disruptive innovation [4]. - Notable initiatives include the establishment of the "Dezhou City Bile Acid Synthesis Biomanufacturing Technology Innovation Center" to build a competitive edge in synthetic biology [4]. Group 4: Platform Functionality and Management - The platforms are categorized into basic research and technology development, focusing on long-term scientific support and addressing key industry challenges [4]. - Future efforts will include enhancing existing platforms, managing performance dynamically, and ensuring alignment with industry needs to stimulate innovation [5].

由药融圈&Synbio深波联合发起，药融圈产业研究院精心编纂的 《2025中国合成生物制造产业发 展白皮书》 （以下简称《研究报告》），已于8月1日 在Synbio China 第三届中国合成生物学"科 学家+企业家+投资家"博览会正式发布！ 本白皮书介绍了生物制造的发展现状及趋势，分析了生物制造的产业链和重点应用方向， 并精选 出中国生物制造产业10大链主企业，整理了15家上市公司合成生物学布局方向以及20大热门品种 ，同时探讨了生物制造面临的挑战，最终提出了针对性的政策建议，供业内参考 。 领取方式： 关注本公众号，扫码添加下方微信获取 添加请备注：单位+职位+姓名 封面一览 Synthetic Biology 深波 1 251 息息与人脉精准链接平台 2025中国合成生物 制造产业发展白皮书 近年来，生物制造的热度居高不下，作为新兴的战略性领域，生物制造因其创新性和对传 统生产方式的颠覆性，被视为新的增长点，有助于推动产业结构优化和经济模式的转变。 China's synthetic biomanufacturing industry Development White Paper 目录 一、 凯赛生物 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 近日， 珠海麦得发生物科技股份有限公司 （以下简称"麦得发"）宣布完成B轮融资，本轮融资由中国太平创新、广药资本联合注资。 据资料显示，随着合成生物学技术持续突破与生产成本逐步下降，PHA产能预计将快速提升，到2029年全球产能有望接近100万吨，约占生物降解塑料总 产能的四分之一，成为高端医疗、特种包装等场景的核心替代材料。 2026年3月31日-4月1日， " 第五届中国合成生物学及生物制造大会 " 将 在 杭州 隆重举行，其中设置 【 生物基化学品与材料专场 】 ，诚邀各位专家及相关从业者 参会交流！ 本次融资资金将 主要用于 PHA（聚羟基脂肪酸酯） 上下游管线持续研发生产、全球市场拓展及核心团队升级建设 。 据悉，麦得发成立于2019年，专注于研究、开发、生产及商业化最新一代纯生物基全域降解材料PHA及其高值健康小分子，并积极探索其在绿色健康、 医疗健康和营养健康等前沿领域的创新应用。 作为聚焦新一代纯生物基全域降解材料的创新企业，麦得发凭借自主知识产权的菌种构 ...